These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 27259298)

  • 1. Type II Diabetes Patients with Proteinuria and the Recovery of Their Metabolic Parameters.
    Ya-Zhuo L; Keqi W; Xiang L; Bin C
    Cell Biochem Biophys; 2015 Dec; 73(3):593-5. PubMed ID: 27259298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Type II diabetes patients with proteinuria and the recovery of their metabolic parameters.
    Liu YZ; Wang K; Li X; Chen B
    Minerva Endocrinol; 2016 Dec; 41(4):486-9. PubMed ID: 27600642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Type II diabetes patients with proteinuria and the recovery of their metabolic parameters.
    Liu YZ; Wang K; Li X; Chen B
    Minerva Endocrinol; 2015 Mar; ():. PubMed ID: 25812668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
    Lewis EJ; Lewis JB
    Clin Exp Nephrol; 2003 Mar; 7(1):1-8. PubMed ID: 14586737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulating effect of atorvastatin on paraoxonase 1 activity in type 2 diabetic Egyptian patients with or without nephropathy.
    Abdin AA; Hassanien MA; Ibrahim EA; El-Noeman Sel-D
    J Diabetes Complications; 2010; 24(5):325-33. PubMed ID: 19553142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy.
    Krairittichai U; Chaisuvannarat V
    J Med Assoc Thai; 2009 May; 92(5):611-7. PubMed ID: 19459520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [IRMA-pRAcs: irbesartan in the treatment of microalbuminuria and proteinuria in patients with type 2 diabetes and hypertension-prospective observational study involving 38,016 patients in the general practice setting].
    Lehnert H; Bramlage P; Pittrow D; Kirch W
    MMW Fortschr Med; 2003 Oct; 145 Suppl 3():81-7. PubMed ID: 15490772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism.
    Pessina AC; Ciccariello L; Perrone F; Stoico V; Gussoni G; Scotti A; Muggeo M
    Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):137-47. PubMed ID: 16487914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Study of ACEI versus ARB in managing hypertensive overt diabetic nephropathy: long-term analysis.
    Ozturk S; Sar F; Bengi-Bozkurt O; Kazancioglu R
    Kidney Blood Press Res; 2009; 32(4):268-75. PubMed ID: 19776644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Risk and prevention of diabetic nephropathy].
    Ravera M; Re M; Deferrari G
    G Ital Nefrol; 2007; 24 Suppl 38():13-9. PubMed ID: 17922442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pioglitazone reduces urinary protein and urinary transforming growth factor-beta excretion in patients with type 2 diabetes and overt nephropathy.
    Katavetin P; Eiam-Ong S; Suwanwalaikorn S
    J Med Assoc Thai; 2006 Feb; 89(2):170-7. PubMed ID: 16579002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decline of renal function is associated with proteinuria and systolic blood pressure in the morning in diabetic nephropathy.
    Suzuki H; Kanno Y; Nakamoto H; Okada H; Sugahara S
    Clin Exp Hypertens; 2005; 27(2-3):129-38. PubMed ID: 15835375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Nephroprotection in young type 1 diabetic patients treated with converting enzyme inhibitor].
    Benamar L; Laboudi A; Rhou H; Laouad I; Fahi Z; Bentata Y; Amar Y; Ezzaïtouni F; Ouzeddoun N; Bayahia R; Balafrej L; Touzani A; Benhamou B; Balafrej A; Guedira A
    Presse Med; 2003 Apr; 32(14):638-43. PubMed ID: 12714902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiproteinuric effect of blood-pressure-lowering agents: a meta-analysis of comparative trials.
    Gansevoort RT; Sluiter WJ; Hemmelder MH; de Zeeuw D; de Jong PE
    Nephrol Dial Transplant; 1995 Nov; 10(11):1963-74. PubMed ID: 8643149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Awareness of albuminuria in an Italian population-based cohort of patients treated with hypoglycemic drugs.
    Degli Esposti L; Saragoni S; Buda S; Sturani A; Quintaliani G; Bartolucci S; Di Turi R; Lilli P; Didoni G; Degli Esposti E
    J Nephrol; 2012; 25(3):325-31. PubMed ID: 21748718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating cholesterol as a modulator of risk for renal injury in patients with type 2 diabetes.
    Earle KA; Harry D; Zitouni K
    Diabetes Res Clin Pract; 2008 Jan; 79(1):68-73. PubMed ID: 17766000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of acarbose on blood glucose and proteinuria in patients with diabetic nephropathy.
    Tomino Y; Shirato I; Horikoshi S; Fukui M; Yamaguchi Y; Yokomatsu M; Ebihara I; Shimada N; Hishiki T; Hirano K; Rinno H; Shiota J; Kuramoto T
    Nephron; 2000 Jun; 85(2):190. PubMed ID: 10867532
    [No Abstract]   [Full Text] [Related]  

  • 19. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.
    de Zeeuw D; Remuzzi G; Parving HH; Keane WF; Zhang Z; Shahinfar S; Snapinn S; Cooper ME; Mitch WE; Brenner BM
    Kidney Int; 2004 Jun; 65(6):2309-20. PubMed ID: 15149345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
    Vogt L; Kocks MJ; Laverman GD; Navis G
    Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.